Department of Pharmacy, Akita University Hospital, Akita, Japan.
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
J Clin Pharm Ther. 2021 Feb;46(1):219-222. doi: 10.1111/jcpt.13257. Epub 2020 Sep 28.
Some patients with chronic myeloid leukaemia (CML) cannot continue tyrosine kinase inhibitor (TKI) treatment due to intolerance associated with higher plasma concentration.
A 76-year-old woman with chronic-phase CML who showed resistance/intolerance to pre-TKIs has been treated with ponatinib. A high ponatinib bioavailability was noted; therefore, we administered ponatinib 15 mg/3 d to avoid adverse events due to high exposure. Eventually, the patient achieved a major molecular response.
Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.
一些慢性髓性白血病（CML）患者由于与较高血浆浓度相关的不耐受而无法继续接受酪氨酸激酶抑制剂（TKI）治疗。
一名 76 岁女性患有慢性期 CML，对前 TKI 具有耐药/不耐受性，一直接受 ponatinib 治疗。发现 ponatinib 具有较高的生物利用度；因此，我们给予 ponatinib 15mg/3d 以避免因高暴露引起的不良事件。最终，患者达到了主要分子缓解。
对 ponatinib 血浆浓度的监测使具有较高药物生物利用度的患者能够安全有效地管理 CML。
